The short version, drug by drug
Whether a GLP-1 can undermine your birth control comes down to one mechanism — how much the drug slows the stomach — and whether that slowing meaningfully cuts how much of the pill's hormones you absorb. On that question, the two main drug families behave differently.
Semaglutide (the ingredient in Ozempic, Wegovy, and the oral tablet Rybelsus) is not expected to reduce the effectiveness of oral contraceptives. Tirzepatide (the ingredient in Mounjaro and Zepbound) carries a specific FDA-label caution to use a backup or non-oral method during the periods when the interaction is strongest. Older GLP-1s such as liraglutide, dulaglutide, and exenatide have not shown a clinically relevant effect on the pill either. The single practical takeaway: if you're on tirzepatide, the label wants you protected with a second method during start-up and dose increases; if you're on semaglutide, that specific warning does not apply — but any pregnancy-prevention decision belongs with your clinician.
- Semaglutide (Ozempic, Wegovy, Rybelsus): no label warning; pill effectiveness not expected to drop.
- Tirzepatide (Mounjaro, Zepbound): label warns the pill may be less effective; backup or non-oral method advised for defined windows.
- Any non-oral hormonal method (IUD, implant, shot, patch, ring): not affected by either drug.
Comparison table: GLP-1s and oral birth control
The table below summarizes what each product's current U.S. prescribing information says about oral hormonal contraceptives. "Barrier method" means condoms or a diaphragm; "non-oral hormonal" means an IUD, implant, injection, patch, or vaginal ring, which are not swallowed and so aren't affected by delayed stomach emptying.
Why tirzepatide is the exception
Tirzepatide's own FDA label is explicit. Under Use in Specific Populations (Section 8.3), the Mounjaro and Zepbound prescribing information states: "Use of [the drug] may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time." It then advises patients on oral contraceptives to "switch to a non-oral contraceptive method or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation."
The reason is pharmacokinetic. Tirzepatide slows how fast the stomach empties, and that effect is strongest right after starting and right after each dose bump. A 2026 systematic review in Obstetrics & Gynecology found that tirzepatide (and some short-acting GLP-1s) reduced the peak concentration of the progestin levonorgestrel by roughly 45–66% and total exposure by about 18–23% in pharmacokinetic studies — enough for the FDA to require the label caution, even though estrogen (ethinyl estradiol) exposure was generally preserved. That is why the guidance targets the specific high-risk windows — the first month on the drug and the first month after every dose increase — rather than the whole course of treatment.
Important nuance: this warning is for oral hormonal contraceptives — pills. The label notes that "hormonal contraceptives that are not administered orally should not be affected." An IUD, implant, injection, patch, or ring bypasses the stomach entirely, so tirzepatide's delayed gastric emptying doesn't change how those methods work.
- Mechanism: tirzepatide slows gastric emptying, reducing progestin absorption from the pill.
- Timing: strongest after the first dose and after each dose escalation; it fades as your body adjusts.
- Label advice: non-oral method, or add a barrier method, for 4 weeks after start and 4 weeks after each dose increase.
- Not affected: IUD, implant, shot, patch, ring — anything not swallowed.
Why semaglutide is treated differently
Semaglutide also slows gastric emptying, but the effect on the pill has not been clinically meaningful in testing, and its label reflects that. The Ozempic and Wegovy prescribing information carries no instruction to use backup contraception with oral birth control. In clinical pharmacology studies, semaglutide "did not affect the absorption of orally administered medications to a clinically relevant degree."
The contraceptive-specific data back this up. A dedicated pharmacokinetic trial (Kapitza et al., published in the Journal of Clinical Pharmacology in 2015) found that semaglutide did not reduce the bioavailability of a combined pill containing ethinyl estradiol and levonorgestrel; estrogen exposure was unchanged and progestin exposure was actually about 20% higher — a change considered not clinically relevant and not expected to reduce the pill's effectiveness. The UK Faculty of Sexual and Reproductive Healthcare (FSRH), in a 2025 statement, concluded that tirzepatide is the only GLP-1 agonist shown to have a clinically significant effect on oral-contraceptive bioavailability, and that no clinically relevant reduction has been seen with semaglutide, exenatide, liraglutide, dulaglutide, or lixisenatide.
One honest caveat: a 2026 case report described the first documented pregnancy on a combined pill during semaglutide use. The authors framed it as a rare event and stressed that population-level evidence still shows semaglutide generally preserves pill hormone exposure. It is a reminder that no contraceptive is 100% effective and that individual factors matter — which is exactly the kind of thing to raise with your prescriber rather than to self-manage.
"Ozempic babies": what's really going on
"Ozempic babies" is the nickname for unexpected pregnancies among people using GLP-1 medications — including some who had struggled with infertility for years. It became a social-media phenomenon, and clinicians at major centers say the pattern is real. Cleveland Clinic (2025) quotes an OB/GYN saying "it's not an overstatement to say we're seeing an Ozempic baby boom." But the reasons are mostly about fertility, not just the pill.
The leading explanation is that weight loss and metabolic improvement can restore ovulation. Obesity disrupts the hormonal balance that regulates the menstrual cycle, and conditions like PCOS and type 2 diabetes — both linked to excess weight — are associated with irregular ovulation and difficulty conceiving. As people lose weight on a GLP-1, cycles can normalize and fertility can rebound, sometimes quickly and unexpectedly. Cleveland Clinic notes that fertility can rise for people whose partners take these drugs too, via improvements in testosterone and sperm parameters. GLP-1s are not fertility treatments and are not FDA-approved for that purpose — increased fertility is a downstream effect of the metabolic changes.
A second, smaller contributor is the pill-absorption issue described above — relevant mainly for tirzepatide, and mainly during start-up and dose changes. A 2025 BMJ fact-check and 2025 National Geographic reporting both concluded that restored fertility from weight loss is the dominant driver of the "Ozempic babies" trend, with any contraceptive-absorption effect a secondary factor that is best documented for tirzepatide. The practical implication is the same regardless of mechanism: if you don't want to become pregnant, don't assume a GLP-1 makes that less likely — it may make it more likely.
- Primary driver: weight loss and better metabolic health can restore ovulation, especially with PCOS or type 2 diabetes.
- Secondary driver: reduced pill absorption — best documented for tirzepatide, during start-up and dose increases.
- GLP-1s are not fertility drugs and aren't approved to treat infertility; the effect is a side effect of weight loss.
Pregnancy and GLP-1s: the safety context
GLP-1 medications are not recommended during pregnancy. The Ozempic, Wegovy, Mounjaro, and Zepbound labels all note, based on animal reproduction studies, potential risk of fetal harm, and advise stopping the medication when pregnancy is recognized. For weight-management use specifically, labels point out that weight loss offers no benefit during pregnancy.
Because semaglutide stays in the body a long time, its labeling and multiple regulators advise discontinuing it at least 2 months before a planned pregnancy. If you are actively trying to conceive, or think you might be pregnant, that is a conversation to have with your prescriber about how to transition off the medication and manage your underlying condition. Early data have been cautiously reassuring — a small study of first-trimester GLP-1 exposure did not show a large increase in major malformations — but the datasets are small and researchers agree more evidence is needed. None of this is a reason to panic if a pregnancy happens on a GLP-1; it is a reason to contact your clinician promptly rather than making changes on your own.
- Labels advise stopping the drug when pregnancy is recognized (animal-study fetal-harm signal).
- Semaglutide: discontinue at least 2 months before a planned pregnancy due to its long half-life.
- If you become pregnant on a GLP-1, contact your prescriber promptly — don't self-manage.
What this means if you're comparing telehealth options
If you're choosing between a semaglutide or tirzepatide program through a telehealth provider, the contraception picture is a legitimate factor to raise during your medical intake — not a reason to pick one drug over another on your own. A licensed prescriber weighs weight-loss goals, other health conditions, cost, and contraception together. What you can do is come prepared: know which method you use, and ask directly how it interacts with the specific medication being prescribed.
A reputable provider should screen for pregnancy risk, ask about your contraception, and counsel you on the tirzepatide backup-method window if that's what you're prescribed. If you want to compare licensed GLP-1 telehealth providers on price, medication options, and clinical support, our comparison tools below can help you shortlist — then bring your contraception questions to the clinician who actually writes the prescription.